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after catheter-based renal denervation (RDN). However, it is unclear whether the number and type of
vascular lesions or the number of ablation points could affect blood pressure (BP) reduction. The aim
of the study was to assess the impact of vascular injury induced by RDN detected with OCT and the
number of ablation points on BP response after 1, 3 and 6 months. METHODS RDN was either performed
with a Simplicity catheter or an EnligHTNTM multielectrode basket followed by OCT. BP was recorded
prospectively as office measurement and 24-hour ambulatory blood pressure monitoring (24-h ABPM) at
each time point. Correlations between type and number of vascular lesions, as well as ablation points,
on BP reduction were performed. RESULTS Out of 16 patients, two were lost to BP follow-up. We
documented a BP reduction at 1, 3 and 6 months in both office and 24-h ABPM. The Δmean office
systolic BP (SBP) reduction was -18.75 ± 24.55 mm Hg, -20.58 ± 16.92 mm Hg and -18.75 ± 29.39 mm
Hg, respectively, and the Δmean 24h-ABPM SBP reduction was -6.50 ± 23.45 mm Hg, -16.88 ± 26.64
mm Hg and -13.89 ± 21.20 mm Hg, respectively. The number of vascular lesions did not correlate with
office and 24h-SBP and diastolic BP reduction. However, there was a correlation between ablation points
and office Δmean SBP reduction at 6 months (p <0.02). CONCLUSIONS Our study demonstrates for
the first time that the number and type of vascular lesions as assessed with OCT did not predict the
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to the number of ablation points at 6 months.
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Summary
Local vascular injury is detectable with optical coherence
tomography (OCT) after catheter-based renal denervation
(RDN). However, it is unclear whether the number and
type of vascular lesions or the number of ablation points
could affect blood pressure (BP) reduction.
The aim of the study was to assess the impact of vascular
injury induced by RDN detected with OCT and the number
of ablation points on BP response after 1, 3 and 6 months.
METHODS: RDN was either performed with a Simpli-
city® catheter or an EnligHTNTM multielectrode basket fol-
lowed by OCT. BP was recorded prospectively as office
measurement and 24-hour ambulatory blood pressure mon-
itoring (24-h ABPM) at each time point. Correlations
between type and number of vascular lesions, as well as ab-
lation points, on BP reduction were performed.
RESULTS: Out of 16 patients, two were lost to BP follow-
up. We documented a BP reduction at 1, 3 and 6 months
in both office and 24-h ABPM. The Δmean office systolic
BP (SBP) reduction was –18.75 ± 24.55 mm Hg, –20.58
± 16.92 mm Hg and –18.75 ± 29.39 mm Hg, respectively,
and the Δmean 24h-ABPM SBP reduction was –6.50 ±
23.45 mm Hg, –16.88 ± 26.64 mm Hg and –13.89 ± 21.20
mm Hg, respectively. The number of vascular lesions did
not correlate with office and 24h-SBP and diastolic BP re-
duction. However, there was a correlation between abla-
tion points and office Δmean SBP reduction at 6 months (p
<0.02).
CONCLUSIONS: Our study demonstrates for the first time
that the number and type of vascular lesions as assessed
with OCT did not predict the success of BP reduction after
RDN. However, we observed a substantial decrease in of-
fice SBP in relation to the number of ablation points at 6
months.
Key words: catheter-based renal nerve ablation; optical
coherence tomography; office blood pressure; 24-hour
ambulatory blood pressure measurement
Introduction
Renal sympathetic denervation (RDN) is a catheter-based
procedure which has been established after first random-
ised trials as a treatment option for patients with resistant
hypertension [1]. Different percutaneous RDN systems are
currently available using different ablation techniques [2].
Given the conflicting results from previous studies and
SYMPLICITY HTN-3 trial the predicted response and suc-
cess after RDN with respect to blood pressure (BP) reduc-
tion is still unknown [3–5].
In this context, there are no data as to whether the number
or type of vascular lesions, irrespective of ablation points,
could potentially affect the results for BP reduction. Fur-
thermore, it is unclear if the amount of ablation points
could affect BP reduction. The Simplicity HTN-2 and
HTN-3 study, which assessed the effectiveness and safety
of RDN with the Simplicity® catheter, did not show any
vascular abnormalities at any sites of radiofrequency deliv-
ery on angiography [1]. However, we have recently shown
with optical coherence tomography (OCT) that renal vas-
cular injury is present after RDN with either the Simpli-
city® catheter or the EnligHTNTM multielectrode basket
[6, 7]. These vascular tissue lesions specifically include
vessel wall oedema, thrombus formation and dissections,
which are not visible with classic coronary angiography.
OCT offers a technique with the immense advantage of
creating high-resolution images allowing accurate tissue
characterisation, and the spatial resolution is approximately
10-fold higher than intravascular ultrasound (IVUS) [8].
Vascular damage such as vessel wall oedema, a common
side effect of RDN, may reflect the effectiveness of renal
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 10
denervation in successfully reducing BP [6]. Furthermore,
extensive tissue damage including all detectable vascular
lesions could lead to a more pronounced decrease in BP.
Therefore, the aim of the present study was to evaluate the
BP response in relation to vascular tissue damage and num-
ber of ablation points after RDN.
Methods
Patient population and catheter-based renal
denervation
This was a sub-analysis of a prospective comparative RDN
OCT study at two cardiology sites in patients with resistant
hypertension [6]. Patient recruitment and inclusion criteria
Figure 1
Blood pressure changes from baseline at 1 month, 3 months and 6
months as determined by office measurement (A) and 24-hour
ambulatory blood pressure measurements (B). Mean
antihypertensive medication intake at baseline and at 6 months of
follow-up (C and D).
AB = alpha-blocker; ACE-I = angiotensin converting-enzyme
inhibitor; ARB = angiotensin receptor blocker; BB = beta-blocker;
CAH = centrally acting antihypertensive; CCB =calcium channel
blocker; DBP = diastolic blood pressure; NO = nitrovasodilator; R-I
= renin inhibitor; RNA = renal nerve ablation; SBP = systolic blood
pressure
Figure 2
Intraluminal local morphological defects in the acute phase just
after the procedure of renal denervation including intraluminal
thrombus formations (A and B), endothelial detachment (C), vessel
wall oedema (D), dissection (E) and massive vascular vasospasm
as detected by the 3D optical coherence tomography
reconstruction.
have been already published elsewhere [6]. Briefly, pa-
tients were included with resistant hypertension, which was
defined as primary or idiopathic with systolic blood pres-
sure (SBP) values >160 mm Hg values and ineffective BP
treatment. Patients were excluded if they had a glomerular
filtration rate <45 ml/min or allergies to contrast medium.
BP was sequentially recorded at 1, 3 and 6 months after
RDN. RDN was either performed with the Simplicity®
catheter (Medtronic-Adrian) or the EnligHTNTM multielec-
trode (St. Jude Medical).
Postdischarge information was obtained as part of our hos-
pital quality assurance using a standardised clinical ques-
tionnaire.
Optical coherence tomography
In all patients OCT was performed using the C7–XR ima-
ging system (Light-Lab Imaging, Inc., Westford, USA) be-
fore and after renal denervation, as previously reported [6].
Vascular lesion characterisation
Oedema was characterized as a significant endothelial-in-
timal notch identified on OCT at the luminal wall surface.
Furthermore, vasospasm and vessel dissections, as well as
thrombus formation (protruding mass with a diameter of ≥5
mm in cross sections), were noted if present [6].
Clinical examination of arterial blood pressure
Blood pressure and heart frequency monitoring was per-
formed in an ambulant setting using an inflatable digital
electrical sphygmomanometer (Microlife® or Omron®
devices) in accordance with the current guidelines. At in-
tervals of 1, 3, and 6 months after RDN, BP was recorded
and compared with baseline data. All patients also under-
went digital 24-hour ambulatory blood pressure monitor-
ing (24–h ABPM) (Spacelab® devices) to analyse daily and
nocturnal variations of the BP profile. In this regard, parti-
cipants were requested not to change daily habits and not to
move their arm during measurements. Furthermore, every
patient was requested to document bed and waking time for
adequate interpretation of the protocol.
Statistical analysis
Continuous variables are given as mean ± standard error of
the mean (SEM) or standard deviation (SD) if appropriate.
Differences between groups were tested using two-sided t-
tests for continuous endpoints when normally distributed
(Shapiro-Wilk test) or Wilcoxon rank-sum test for non-nor-
mally distributed continuous endpoints. Correlation analys-
is was used to determine the association between ablation
points as well as lesions and BP reduction. SPSS software
(Chicago, Illinois; Version 20.0) and Graph pad (Version
5.0) were applied for statistical analysis. A p-value <0.05
was considered as statistical significant.
Results
Sixteen patients were enrolled in the study and two patients
were lost to blood pressure follow-up. Baseline character-
istics are shown in table 1. The mean baseline office systol-
ic BP was 168.50 ± 18.29 mm Hg and 24-h ABPM was
159.29 ± 16.37 mm Hg. During repeat BP measurement at
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1, 3 and 6 months the mean office systolic BP was 150.83 ±
19.14 mm Hg, 146.50 ± 15.58 mm Hg and 147.42 ± 18.42
mm Hg, respectively. The mean systolic 24-h ABPM was
155.25 ± 16.15 mm Hg, 138.25 ± 13.33 mm Hg and 141.00
± 15.91 mm Hg, respectively. We documented an essential
Δmean BP reduction at all time-points in both office and
24-h ABPM (fig. 1A and B, table 2). At 1, 3 and 6 months,
the office Δmean systolic BP (SBP) reduction was –18.75 ±
24.55 mm Hg, –20.58 ± 16.92 mm Hg and –18.75 ± 29.39
mm Hg, respectively, and the Δmean 24-h ABPM SBP re-
duction was –6.50 ± 23.45 mm Hg, 16.88 ± 26.64 mm Hg
and 13.89 ± 21.20 mm Hg, respectively.
By 6 months, patients were able to reduce antihypertensive
therapy from 4.14 ± 1.88 drugs at baseline to 3.00 ± 2.00 at
follow-up (fig. 1C and D).
During renal denervation procedures, 197 ablation points
were performed in 28 renal arteries. Patients received an
average of 7.0 ± 1.3 ablations per renal artery (range 4 to
11). There were no major clinical complications related to
the RDN procedure as previously reported.
The OCT pullbacks performed before and after each pro-
cedure documented in total 141 different local acute mor-
phological vascular changes. In detail, 60 areas of promin-
ent oedema, 57 intraluminal thrombi, 21 vessel vasospasms
and 3 wall dissections were observed (fig. 2). The total
amount of all vascular lesions including the combination of
oedema, thrombus formation, dissections and spasms did
not reveal any correlation to BP reduction at 1, 3 and 6
months follow-up (office BP and 24-h ABPM) (fig. 3). Fur-
thermore, no correlation between oedema and BP reduction
was documented at any time of follow-up (fig. 4).
Interestingly, at 6 months of follow-up there was a correla-
tion between the total number of ablation points and systol-
ic BP reduction, although no correlation was observed at
earlier follow-up time-points (1 and 3 months) (r = –0.66,
p <0.02) (fig. 5). Complete correlation analysis is given in
table 2.
Discussion
Although previously the effectiveness of RDN in reducing
blood pressure in patients with resistant hypertension has
been documented by different investigations and random-
ised trials [1, 3, 9–11], the SYMPLICITY HTN-3 trial
failed to confirm these results [5].
Conflicting data on RDN efficacy in resistant hypertension
could be caused by many factors including different study
design, lack of statistical power, effectiveness of the RDN
procedure, mixed medication therapy, and different patient
populations [12].
To date, no harmful long-term effects of RDN have been
observed and the safety profile [13] has been studied by re-
Table 2: Correlations between optical coherence tomography findings and blood pressure (BP) in follow up (n = 14).
Office BP 24-hour ambulatory BP monitoring
Systolic BP Diastolic BP Systolic BP Diastolic BP
Follow up 1 month 3 months 6 months 1 month 3 months 6 months 1 month 3 months 6 months 1 month 3 months 6 months
Δmean –18.750 –20.580 –18.750 –11.830 –10.250 –13.000 –6.500 –16.880 –13.890 –6.250 –6.500 –8.667
SD 24.550 16.920 29.390 16.080 13.420 17.320 23.450 26.640 21.200 11.510 16.170 10.750
Ablation points
p-value 0.113 0.063 0.019 0.060 0.499 0.221 0.100 0.589 0.489 0.114 0.266 0.301
r –0.482 –0.551 0.664 –0.558 –0.217 –0.382 –0.622 –0.227 –0.266 –0.602 –0.448 –0.389
Lesions (overall)
p-value 0.792 0.581 0.262 0.819 0.246 0.610 0.458 0.735 0.463 0.760 0.877 0.957
r –0.085 –0.178 –0.352 –0.074 –0.363 –0.164 0.308 0.144 0.282 0.130 0.066 0.021
Oedemas
p-value 0.948 0.351 0.958 0.924 0.041 0.143 0.443 0.709 0.572 0.893 0.716 0.712
r –0.021 0.295 –0.017 0.031 0.596 0.450 0.318 0.158 0.219 –0.057 –0.154 –0.144
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peated renal angiograms and magnetic resonance imaging
(MRI) [9]. Recently, we have shown that, despite the above
mentioned safety issues, local tissue damage at the abla-
tion sites such as oedema, dissection and thrombus forma-
tion can occur after RDN, and that OCT has the ability to
visualise vascular lesions, which are primarily not appar-
ent on angiography [6]. The present study explored the im-
pact of endothelial damage after RDN on blood pressure
reduction in order to identify a potential marker in terms of
morphological tissue damage that may predict the response
to RDN; this would be of major interest also potentially
to explain non-responsiveness, which is estimated to affect
between 8–16% of patients [9, 14]. Although it is specu-
lated that non-responsiveness might be attributed to a dif-
ferent mechanism of hypertension, which is not caused by
sympathetic hyperactivity, non-responsiveness may also be
Table 1: Baseline Characteristics (n = 14).
Age, years 57.8 ± 9.9
Gender, male 8 (57)
Cardiovascular
history
Known CAD or
stroke
4 (29)
Cardiovascular
risk factors
Hypertension 14 (100)
Hyperlipidaemia 9 (64)
Smoking,
current
6 (43)
Obesity 7 (50)
Diabetes
mellitus
3 (21)
Medication on
admission
Aspirin 4 (29)
Clopidogrel 1 (7)
Statin 7 (50)
Beta-blocker 10 (71)
ACEI/AT-II 11 (79)
Diuretics 11 (79)
CCB 7 (50)
Depicted are counts, n, incidence (%) or mean ± SD
ACEI = angiotensin converting-enzyme inhibitors; AT-II =
angiotensin-receptor blocking agents; CAD = coronary artery
disease; CCB = calcium-channel blocker
Figure 3
Correlation between blood pressure (BP) reduction (Δmean office
and 24-hour ambulant blood pressure monitoring [ABPM]) and
vascular lesions.
DBP = diastolic blood pressure; SBP = systolic blood pressure
monitoring
caused by technical aspects, i.e. in patients with dual ren-
al arteries and/or accessory arteries not accessible for RDN
and advanced vascular remodelling [15].
In line with previously published trials [3, 9, 10, 14,
16–21], we documented a reduction in systolic and diastol-
ic BP as assessed by office and 24-h ABPM at 1, 3 and 6
months of follow up.
Furthermore, we also show that the total amount of local
vascular lesions could not predict the success of blood pres-
sure reduction in patients with resistant hypertension. Spe-
cifically, vessel wall oedema which is well defined by OCT
and histologically corresponds to cellular swelling and con-
nective tissue coagulation within the medial and adventi-
tial layers [22] failed to show an effect on blood pressure
reduction. Although preclinical studies have demonstrated
that 17% of the artery wall circumference is affected by a
transmural injury after RDN affecting particularly the me-
dia and adventitia [22], it is conceivable that most observed
vascular wall oedema represents only a surface response to
RDN, and that most of the sympathetic nerve fibres in the
adventitial layer are impacted by OCT, with invisible dam-
age caused by the applied high-frequency energy. In this re-
spect, OCT has a very high spatial resolution, but the pen-
etration depth is limited, particularly in large vessels, such
as renal arteries. This is in line with the fact that not all ap-
Figure 4
Correlation between blood pressure (BP) reduction (Δmean office
and 24-hour ambulant blood pressure monitoring [ABPM]) and
oedema.
DBP = diastolic blood pressure; SBP = systolic blood pressure
monitoring
Figure 5
Correlation between blood pressure reduction (BP) (Δmean office
and 24-hour ambulant blood pressure monitoring [ABPM]) and
ablation points.
DBP = diastolic blood pressure; SBP = systolic blood pressure
monitoring
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plied ablation points correspond to vessel wall oedema. In
this regard, it has been shown that newer-generation RDN
devices such the One Shot balloon from Covidien did not
result in any vascular lesion [23], although the clinical re-
sponse on BP reduction has been shown in previous studies
[20]. Therefore, it seems that local vascular lesions induced
at the vascular surface are not able to predict the success of
RDN in terms of BP reduction. It is more likely that deeper
damage in the vessel wall (e.g. in the adventitial layer) is
responsible for the success of RDN; however, these lesions
are undetectable with OCT.
Recently, Vogel et al. demonstrated no impact of applied
ablation points on BP reduction [24]. In contrast to these
results, in the present study we demonstrated a correlation
between ablation points and systolic BP reduction at 6
months follow up. However, future studies are needed to
confirm this preliminary observation in a larger patient
population.
Study limitations
The number of patients studied is still small to draw final
conclusions, but this is the first study that demonstrated
with OCT that vascular lesions apparently do not influence
the blood pressure outcome. Larger studies are warranted
to assess carefully patients who will benefit from RDN and
to define solid predictors for the success of RDN. Since
OCT has a limited penetration depth, renal nerves localised
in the adventitial layer of the arterial wall cannot be directly
visualised [25]. Vascular lesions are contact points between
ablation electrode and arterial wall. However, these points
should be related to the nerve ablation points localized in
adventitia.
Conclusions
This study for the first time indicates that the magnitude
and type of vascular lesions induced by RDN as assessed
by OCT could not predict the success of blood pressure re-
duction in patients with resistant hypertension. In addition,
we observed a significant correlation between the number
of applied ablation points and SBP reduction after 6 months
of follow up. Therefore, not the vascular lesions but the ab-
lation points could serve as an important predictor for the
success of blood pressure reduction.
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Figures (large format)
Figure 1
Blood pressure changes from baseline at 1 month, 3 months and 6 months as determined by office measurement (A) and 24-hour ambulatory
blood pressure measurements (B). Mean antihypertensive medication intake at baseline and at 6 months of follow-up (C and D).
AB = alpha-blocker; ACE-I = angiotensin converting-enzyme inhibitor; ARB = angiotensin receptor blocker; BB = beta-blocker; CAH = centrally
acting antihypertensive; CCB =calcium channel blocker; DBP = diastolic blood pressure; NO = nitrovasodilator; R-I = renin inhibitor; RNA = renal
nerve ablation; SBP = systolic blood pressure
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Figure 2
Intraluminal local morphological defects in the acute phase just after the procedure of renal denervation including intraluminal thrombus
formations (A and B), endothelial detachment (C), vessel wall oedema (D), dissection (E) and massive vascular vasospasm as detected by the
3D optical coherence tomography reconstruction.
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Figure 3
Correlation between blood pressure (BP) reduction (Δmean office and 24-hour ambulant blood pressure monitoring [ABPM]) and vascular
lesions.
DBP = diastolic blood pressure; SBP = systolic blood pressure monitoring
Figure 4
Correlation between blood pressure (BP) reduction (Δmean office and 24-hour ambulant blood pressure monitoring [ABPM]) and oedema.
DBP = diastolic blood pressure; SBP = systolic blood pressure monitoring
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Figure 5
Correlation between blood pressure reduction (BP) (Δmean office and 24-hour ambulant blood pressure monitoring [ABPM]) and ablation
points.
DBP = diastolic blood pressure; SBP = systolic blood pressure monitoring
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